FY09 DOD Lung Cancer Clinical Fellow Research Award

The summary for the FY09 DOD Lung Cancer Clinical Fellow Research Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

FY09 DOD Lung Cancer Clinical Fellow Research Award: The LCRP Clinical Fellow Research Award (CFRA) supports a research project performed by a clinical fellow under the guidance of a designated mentor having an established lung cancer research program. This award is intended to prepare fellows with clinical duties and/or responsibilities for a career in lung cancer research. The Principal Investigator (PI) must be in either an accredited medical residency or medical fellowship program. The DOD LCRP strongly encourages submissions from, and partnerships with, investigators at Military Treatment Facilities, Military Research Institutions, and the Department of Veterans Affairs (VA) Medical Centers and research laboratories.Funds from this award are intended to provide aggressive protection, of at least 40%, of the clinical fellow's time for research. The clinical fellow must demonstrate a strong commitment to a career in lung cancer research and clinical practice.Areas of Emphasis: The FY09 LCRP CFRA ONLY accepts applications that address at least one of the seven Areas of Emphasis listed below:- Identification or development of non-invasive or minimally invasive tools to improve the detection of the initial stages of lung cancer- Identification and development of tools for screening or early detection of lung cancer. Screening may include, but is not limited to, computed tomography scans, X-rays, other imaging, biomarkers, genetics/genomics/proteomics, and assessment of risk factors- Understanding the molecular mechanisms that lead to clinically significant lung cancer- Identification of the mechanisms that lead to the development of the various types of lung cancer- Identification of innovative strategies for prevention and treatment of early lung cancer- Understanding predictive and prognostic markers to identify responders and non-responders- Understanding acquired resistance to treatmentSee the Program Announcement for the full Funding Opportunity Description.